1 |
Cacabelos R, Carril JC, Corzo L, Pego R, Cacabelos N, Alcaraz M, Muñiz A, Martínez-Iglesias O, Naidoo V. Pharmacogenetics of anxiety and depression in Alzheimer's disease. Pharmacogenomics 2023;24:27-57. [PMID: 36628952 DOI: 10.2217/pgs-2022-0137] [Reference Citation Analysis]
|
2 |
Nagata T, Shinagawa S, Inamura K, Shigeta M. Pathogenesis and Personalized Interventions for Pharmacological Treatment-Resistant Neuropsychiatric Symptoms in Alzheimer’s Disease. JPM 2022;12:1365. [DOI: 10.3390/jpm12091365] [Reference Citation Analysis]
|
3 |
Cacabelos R, Naidoo V, Martínez-iglesias O, Corzo L, Cacabelos N, Pego R, Carril JC. Personalized Management and Treatment of Alzheimer’s Disease. Life 2022;12:460. [DOI: 10.3390/life12030460] [Reference Citation Analysis]
|
4 |
Cacabelos R. What have we learnt from past failures in Alzheimer's disease drug discovery? Expert Opin Drug Discov 2022;:1-15. [PMID: 35129021 DOI: 10.1080/17460441.2022.2033724] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
5 |
Cacabelos R, Naidoo V, Martínez-iglesias O, Corzo L, Cacabelos N, Pego R, Carril JC. Pharmacogenomics of Alzheimer’s Disease: Novel Strategies for Drug Utilization and Development. Methods in Molecular Biology 2022. [DOI: 10.1007/978-1-0716-2573-6_13] [Reference Citation Analysis]
|